Joy Clairmont is a shareholder in the Whistleblower, Qui
Tam & False Claims Act Group at Berger & Montague,
which has recovered more than $3 billion for federal and state
governments, as well as over $500 million for the firm's
whistleblower clients. Ms. Clairmont also has experience
practicing in the area of securities fraud litigation.
Ms. Clairmont has been investigating and litigating
whistleblower cases for over fifteen years and has successfully
represented whistleblower clients in federal and state courts
throughout the United States. On behalf of her whistleblower
clients, Ms. Clairmont has pursued fraud cases involving a diverse
array of companies: behavioral health facilities, a national retail
pharmacy chain, a research institution, pharmaceutical
manufacturers, skilled nursing facilities, a national dental chain,
mortgage lenders, hospitals and medical device manufacturers.
Most notably, Ms. Clairmont has participated in several
significant and groundbreaking cases involving fraudulent drug
● United States ex rel. Streck v. AstraZeneca, LP, et
al., C.A. No. 08-5135 (E.D. Pa.): a Medicaid rebate
fraud case which settled in 2015 for a total of $55.5 million
against three pharmaceutical manufacturers, AstraZeneca, Cephalon,
and Biogen. The case alleged that the defendants did not
properly account for millions of dollars of payments to wholesalers
for drug distribution and other services. As a result, the
defendants underpaid the government in rebates owed under the
Medicaid Drug Rebate Program.
● United States ex rel. Kieff and LaCorte v. Wyeth and
Pfizer, Inc., Nos. 03-12366 and 06-11724-DPW (D.
Mass.): a Medicaid rebate fraud case involving Wyeth's
acid-reflux drug, Protonix, which settled for $784.6 million
in April 2016.
● "AWP" Cases: a series of cases in federal and state courts
against many of the largest pharmaceutical manufacturers, including
Brisol-Myers Squibb, Boehringer Ingelheim, and GlaxoSmithKline, for
defrauding the government through false and inflated price reports
for their drugs, which resulted in more than $2 billion in
recoveries for the government.
Earlier in her career, Ms. Clairmont gained experience
litigating securities fraud class actions including, most notably,
In Re Sunbeam Securities Litigation, a class action
which led to the recovery of over $142 million for the class of
plaintiffs in 2002.
Ms. Clairmont graduated in 1995 with a B.A. cum
laude from George Washington University and in 1998 with a
J.D. from George Washington University Law School.
Prominent Judgments & Settlements
Some of the more significant cases in which Ms. Clairmont has
been involved include:
- United States et al. ex rel. Lauren Kieff v. Wyeth
Pharmaceuticals, Inc., Civil Action No. 03-CV-12366-DPW (D.
- United States ex rel. Ven-a-Care of the Florida Keys Inc.
v. Dey Laboratories, et al., Civil Action No. 05-11084 (D.
Mass) ($280 Million settlement in December 2010).
- State of Florida v. Dey et
al., Civil Action No. 98-3032A (Leon Cty., Fla.) ($15
million settlement - $6.5 million settlement with Dey; $8.5 million
settlement with Roxane).
States v. AstraZeneca Pharmaceuticals, LP, Civil Action
No. 06-231 (D. N.H.) ($124 million combine settlement with
AstraZeneca, Mylan, UDL and Ortho-McNeil).
Unites States v. Bristol-Myers Squibb Co., Civil
Action No. 95-1354 (S.D. Fla.) ($515 million global settlement
against Bristol and its subsidiary Apothecon).
- State of Texas ex rel. Ven-A-Care of the Florida Keys
Inc. v. Warrick Pharmaceuticals et al., Civil Action No.
GV002327 (Travis Cty., Tex.) ($27 million settlement with
- In re
Sunbeam Securities Litigation, Case No. 98-8258 (S.D.
Fla.) ($142 million securities fraud settlement).
- In re Clarus Corp. Secur. Litig., 201 F. Supp. 2d
1244 (N.D. Ga. 2002).